Ora Rosengarten

3.9k total citations · 1 hit paper
33 papers, 2.0k citations indexed

About

Ora Rosengarten is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Ora Rosengarten has authored 33 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Cancer Research and 11 papers in Genetics. Recurrent topics in Ora Rosengarten's work include Ovarian cancer diagnosis and treatment (11 papers), BRCA gene mutations in cancer (9 papers) and Cancer Genomics and Diagnostics (6 papers). Ora Rosengarten is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), BRCA gene mutations in cancer (9 papers) and Cancer Genomics and Diagnostics (6 papers). Ora Rosengarten collaborates with scholars based in Israel, United States and United Kingdom. Ora Rosengarten's co-authors include Georgeta Fried, Salomon M. Stemmer, Bella Kaufman, Ayala Hubert, Judith Balmañà, Gillian Mitchell, Michael Friedländer, Susan M. Domchek, Ronnie Shapira‐Frommer and M. William Audeh and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Ora Rosengarten

31 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

2014 1.2k citations Bella Kaufman, Ronnie Shapira‐Frommer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ora Rosengarten Israel	12	1.5k	738	497	467	461	33	2.0k
Sharad Ghamande United States	22	770 0.5×	579 0.8×	216 0.4×	476 1.0×	128 0.3×	114	1.7k
Rachel N. Grisham United States	23	669 0.5×	596 0.8×	233 0.5×	871 1.9×	281 0.6×	119	1.7k
John L. Hays United States	23	765 0.5×	658 0.9×	239 0.5×	314 0.7×	150 0.3×	98	1.6k
Maria Ornella Nicoletto Italy	18	581 0.4×	496 0.7×	324 0.7×	445 1.0×	142 0.3×	54	1.3k
Carmela Pisano Italy	26	706 0.5×	532 0.7×	292 0.6×	862 1.8×	97 0.2×	95	1.9k
Sabrina Chiara Cecere Italy	20	615 0.4×	428 0.6×	290 0.6×	525 1.1×	87 0.2×	71	1.4k
Angela Toss Italy	22	663 0.5×	492 0.7×	440 0.9×	283 0.6×	409 0.9×	92	1.5k
Fabian Trillsch Germany	25	577 0.4×	802 1.1×	568 1.1×	712 1.5×	132 0.3×	128	2.1k
Karin Bowen United States	15	1.3k 0.9×	809 1.1×	359 0.7×	334 0.7×	342 0.7×	30	2.8k
Vanda Salutari Italy	23	555 0.4×	333 0.5×	185 0.4×	722 1.5×	166 0.4×	110	1.5k

Countries citing papers authored by Ora Rosengarten

Since Specialization

Citations

This map shows the geographic impact of Ora Rosengarten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ora Rosengarten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ora Rosengarten more than expected).

Fields of papers citing papers by Ora Rosengarten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ora Rosengarten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ora Rosengarten. The network helps show where Ora Rosengarten may publish in the future.

Co-authorship network of co-authors of Ora Rosengarten

This figure shows the co-authorship network connecting the top 25 collaborators of Ora Rosengarten. A scholar is included among the top collaborators of Ora Rosengarten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ora Rosengarten. Ora Rosengarten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schwarz, Norbert Georg, Zvi Vaknin, Ora Rosengarten, et al.. (2025). Increasing incidence of endometrial cancer demands global action. 1(3). e158–e159.

Segev, Yakir, et al.. (2025). Presymptomatic Awareness of BRCA1/BRCA2 Status and Outcomes in Women With Ovarian Cancer. JAMA Network Open. 8(3). e251435–e251435.

Lee, Jung‐Yun, Maria C. Bell, Mariusz Bidziński, et al.. (2023). Abstract CT046: A randomized, phase 2 study of pembrolizumab plus chemotherapy with or without anti—immunoglobulin-like transcript 4 monoclonal antibody MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer. Cancer Research. 83(8_Supplement). CT046–CT046. 1 indexed citations

Stemmer, Salomon M., Mariana Steiner, Shulamith Rizel, et al.. (2019). Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy. npj Breast Cancer. 5(1). 41–41. 23 indexed citations

Rottenstreich, Misgav, et al.. (2019). Recurrence of endometrial carcinoma presenting as vulvar lesions. International Journal of Gynecology & Obstetrics. 145(1). 123–124. 1 indexed citations

Bossi, Paolo, Andrea Antonuzzo, Nathan I. Cherny, et al.. (2018). Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 29(Suppl 4). iv126–iv142. 84 indexed citations

Michaelson‐Cohen, Rachel, Rakefet Chen‐Shtoyerman, Orit Reish, et al.. (2018). Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. Cancer. 125(5). 698–703. 24 indexed citations

Evron, Ella, Georgeta Fried, Bella Kaufman, et al.. (2018). Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer. Annals of Oncology. 30(3). 412–417. 36 indexed citations

Tahover, Esther, Amiel Segal, Rut Isacson, et al.. (2017). Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer. Anti-Cancer Drugs. 28(7). 787–794. 38 indexed citations

10.

Stemmer, Salomon M., Shulamith Rizel, David Geffen, et al.. (2017). Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. npj Breast Cancer. 3(1). 32–32. 68 indexed citations

11.

Stemmer, Salomon M., Shulamit Rizel, Tamar Peretz, et al.. (2016). First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result. Annals of Oncology. 27. vi44–vi44. 3 indexed citations

12.

Mirza, Mansoor Raza, Bradley J. Monk, Amit M. Oza, et al.. (2016). gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Annals of Oncology. 27. vi568–vi568. 7 indexed citations

13.

Stemmer, Salomon M., Shulamith Rizel, Lior Soussan‐Gutman, et al.. (2016). Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%. Cancer Research. 76(4_Supplement). P5–8. 15 indexed citations

14.

Domchek, Susan M., Carol Aghajanian, Ronnie Shapira‐Frommer, et al.. (2015). Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecologic Oncology. 140(2). 199–203. 218 indexed citations

15.

Safra, Tamar, Tara Berman, Ilan Bruchim, et al.. (2013). Weekly Topotecan for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma. International Journal of Gynecological Cancer. 23(3). 475–480. 6 indexed citations

16.

Eitan, Ram, et al.. (2013). Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer. Anti-Cancer Drugs. 25(1). 101–105. 11 indexed citations

17.

Grenader, Tal, et al.. (2012). Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin. World Journal of Clinical Oncology. 3(10). 137–137. 2 indexed citations

18.

Lowery, Maeve A., Manish A. Shah, Elizabeth Smyth, et al.. (2010). A 67-Year-Old Woman with BRCA 1 Mutation Associated with Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer. 42(3). 160–164. 9 indexed citations

19.

Rosengarten, Ora, et al.. (2009). Palliative Sedation at Home. Journal of Palliative Care. 25(1). 5–11. 28 indexed citations

20.

Grenader, Tal, et al.. (2008). Primary Amelanotic Melanoma of the Vagina. Onkologie. 31(8-9). 474–476. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact